News about general reimbursement of medicines

  • Reassessment of reimbursement status

    | 18 December 2006 |

    This summer, the Danish Medicines Agency will begin the periodic reassessment of reimbursement status of medicinal products. Over a 5-year period, the reimbursement status of all medicinal products will be reassessed to ensure that the medicinal products having been granted general reimbursement still meet the required criteria and that medicinal products which have not been granted general reimbursement do not meet the criteria.

  • Reimbursement status of medicinal products aginst hypertension

    | 18 December 2006 |

    On 6 March 2006, the Danish Medicines Agency wrote a letter to a number of scientific societies to make them clarify certain aspects of the treatment of hypertension in Denmark.

  • Reassessment of ATC group A, Alimentary tract and metabolism

    | 18 December 2006 |

    At the beginning of 2007, the Danish Medicines Agency is going to begin the reassessment of ATC group A, alimentary tract and metabolism, starting with.

  • Consultation on recommended changes of the reimbursement status of lipid-lowering medicinal products

    | 18 December 2006 |

    At several meetings, the Reimbursement Committee has discussed the reimbursement status of lipid-lowering medicinal products. In its recommendation of 7 September 2006 for the Danish Medicines Agency, the Committee suggests a change of reimbursement status for these medicinal products.

  • Reassessment of subgroups in ATC group C

    | 24 April 2006 |

    The Danish Medicines Agency is just beginning to reassess the subgroups in ATC group C, medicinal products for the cardiovascular system, and for the first three months of 2006 the agency expects to be working with the following six subgroups.

  • Letter to scientific societies on treatment of hypertension

    | 24 April 2006 |

    As part of the reassessment concerning medicinal products' reimbursement status, the Danish Medicines Agency has begun looking at reimbursement status of medicinal products for hypertension.